metformin has been researched along with ritonavir in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 13 (72.22) | 24.3611 |
| 2020's | 4 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Adekola, KU; Dalva Aydemir, S; Ma, S; Rosen, ST; Shanmugam, M; Zhou, Z | 1 |
| Adekola, KU; Bajpai, R; Dalva-Aydemir, S; Kandela, I; Koblinski, JE; Martinez, M; Raje, NS; Rosen, ST; Shanmugam, M; Singhal, S; Wei, C | 1 |
| Aoki, D; Banno, K; Iida, M; Irie, H; Kobayashi, Y; Masuda, K; Tominaga, E; Yanokura, M | 1 |
| Feng, X; Jiang, Y; Liu, C; Qu, F; Xi, H; Zhao, X; Zhao, Y | 1 |
| Chee, YJ; Tan, SK; Yeoh, E | 1 |
| Adekola, K; Chowdhury, A; Forman, SJ; Hammond, SN; Htut, M; Karanes, C; Krishnan, A; Nathwani, N; Palmer, J; Rosen, ST; Rosenzweig, M; Sahebi, F; Salehian, B; Sanchez, JF; Siddiqi, T; Synold, TW; Tomarchio, V | 1 |
| Bartosch, C; Henriques Abreu, M; Nunes, M; Ricardo, S | 1 |
6 review(s) available for metformin and ritonavir
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug repositioning for gynecologic tumors: a new therapeutic strategy for cancer.
Topics: AMP-Activated Protein Kinases; Cyclooxygenase 2 Inhibitors; Drug Repositioning; Drug Therapy, Combination; Female; Genital Neoplasms, Female; Humans; Metformin; Peroxisome Proliferator-Activated Receptors; Ritonavir | 2015 |
Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening.
Topics: Angiotensin-Converting Enzyme 2; Anti-Inflammatory Agents; Antimalarials; Antiviral Agents; Basal Metabolism; Betacoronavirus; Cardiovascular Physiological Phenomena; Chloroquine; Congenital Abnormalities; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Disease Susceptibility; Drug Combinations; Drug Delivery Systems; Female; Functional Residual Capacity; Glycyrrhizic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Interferon Type I; Lopinavir; Metformin; Nanoparticles; Oxygen Consumption; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Pregnancy; Pregnancy Complications, Infectious; Progesterone; Prognosis; Respiratory Physiological Phenomena; Ritonavir; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Stillbirth; Ventilation-Perfusion Ratio | 2020 |
Dissecting the interaction between COVID-19 and diabetes mellitus.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Blood Glucose; Chloroquine; Comorbidity; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Diabetes Complications; Diabetes Mellitus; Diabetic Ketoacidosis; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucagon-Like Peptide-1 Receptor; Glycemic Control; Humans; Hydroxychloroquine; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Interferon Type I; Lopinavir; Lung; Metformin; Obesity; Pancreas; Ritonavir; Severity of Illness Index; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones | 2020 |
Recycling the Purpose of Old Drugs to Treat Ovarian Cancer.
Topics: Diphosphonates; Drug Repositioning; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Itraconazole; Ivermectin; Metformin; Neoplasm Recurrence, Local; Ovarian Neoplasms; Ritonavir | 2020 |
12 other study(ies) available for metformin and ritonavir
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Investigating and targeting chronic lymphocytic leukemia metabolism with the human immunodeficiency virus protease inhibitor ritonavir and metformin.
Topics: Aged; Cell Survival; Cells, Cultured; Drug Synergism; Energy Metabolism; Female; Glucose; Glucose Transporter Type 4; HIV Protease Inhibitors; Humans; Hypoglycemic Agents; Immunoblotting; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Metformin; Microscopy, Fluorescence; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Oxidative Phosphorylation; Ritonavir; Tumor Cells, Cultured | 2015 |
Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Electron Transport Complex I; Gene Expression; Glucose Transporter Type 4; Glutamine; Humans; Mechanistic Target of Rapamycin Complex 1; Metformin; Mice; Mitochondria; Multiple Myeloma; Multiprotein Complexes; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Invasiveness; Oxygen Consumption; Proto-Oncogene Proteins c-akt; Ritonavir; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Toxicities Associated With Metformin/Ritonavir Combination Treatment in Relapsed/Refractory Multiple Myeloma.
Topics: Combined Modality Therapy; Female; Humans; Metformin; Middle Aged; Multiple Myeloma; Pilot Projects; Ritonavir | 2020 |